Bio-Path Holdings Inc. (NASDAQ: BPTH)
$1.2200
-0.2700 ( -12.23% ) 2.9M
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Market Data
Open
$1.2200
Previous close
$1.4900
Volume
2.9M
Market cap
$5.94M
Day range
$1.0400 - $1.4450
52 week range
$0.5933 - $12.0000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Sep 13, 2024 |
8-k | 8K-related | 15 | Aug 21, 2024 |
8-k | 8K-related | 15 | Aug 15, 2024 |
10-q | Quarterly Reports | 51 | Aug 14, 2024 |
4 | Insider transactions | 1 | Aug 01, 2024 |
4 | Insider transactions | 1 | Aug 01, 2024 |
4 | Insider transactions | 1 | Aug 01, 2024 |
4 | Insider transactions | 1 | Aug 01, 2024 |
4 | Insider transactions | 1 | Aug 01, 2024 |
8-k | 8K-related | 15 | Jul 11, 2024 |